Ask about this productRelated genes to: VCAM1 antibody
- Gene:
- VCAM1 NIH gene
- Name:
- vascular cell adhesion molecule 1
- Previous symbol:
- -
- Synonyms:
- CD106
- Chromosome:
- 1p21.2
- Locus Type:
- gene with protein product
- Date approved:
- 1991-07-10
- Date modifiied:
- 2016-10-05
Related products to: VCAM1 antibody
Related articles to: VCAM1 antibody
- Advanced glycation end products (AGEs), particularly AGE-modified albumin (AGE-BSA), have been implicated in vascular inflammation and endothelial dysfunction, while neutrophil extracellular traps (NETs) are known to aggravate endothelial injury. Here, we investigated whether AGE-BSA directly promotes endothelial inflammatory and thrombotic activation, modulates neutrophil oxidative stress and NET formation, and may enhance NET-induced endothelial inflammation. - Source: PubMed
Publication date: 2026/05/15
Junho Carolina Victoria CruzDai YusangSchieren LuisaHourtz SinaRykova TetianaVondenhoff SonjaWessiepe MartinaZou JinmiJankowski JoachimGoettsch ClaudiaNoels Heidi - Alzheimer's disease (AD) is a progressive neurological disorder associated with high prevalence. Numerous studies have been conducted to regulate the expression of inflammatory genes, indicating that any changes may ultimately lead the nervous system toward disease pathogenesis. ANXA1, VCAM1, and CCL2 are among the genes involved in immune and inflammatory pathways. In this study, we aim to examine their expression in individuals with Alzheimer's disease and healthy individuals using bioinformatics and laboratory methods. - Source: PubMed
Publication date: 2026/05/16
Fattahi FatemeAbed SaminKouchakali GhazalDerakhshan Sima MansooriSadeh Reza NaghdiKhaniani Mahmoud Shekari - Objective peripheral biomarkers for early-stage schizophrenia are needed to improve diagnostic accuracy and treatment planning. To identify potential biomarkers, we compared multiple serum factor concentrations between 90 first-episode drug-naïve patients and healthy matched controls, and further examined associations with symptom severity and cognitive functions among patients. Serum interleukin (IL)-8, vascular cell adhesion molecule (VCAM)-1, matrix metalloproteinase (MMP)-2, and MMP-7 concentrations were quantified by Luminex multiplex immunoassays, and log10-transformed values compared with adjustment for age, sex, years of education, body mass index, and smoking status. Associations with symptoms as assessed by the Positive and Negative Syndrome Scale (PANSS) and cognitive functions as assessed by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) were examined by Pearson's correlation analysis. Multivariable logistic regression models were developed for case-control discrimination by receiver operating characteristic analysis with 10-fold cross-validation and calibration. Serum log10[IL-8] and log10[MMP-7] were higher while serum log10[MMP-2] and log10[VCAM-1] were lower in patients. Serum log10[MMP-2], log10[MMP-7], and log10[VCAM-1] were positively correlated among patients, whereas log10[IL-8] was not associated with this MMP/VCAM-1 axis. There were no stable linear associations with PANSS or RBANS scores. Serum log10[IL-8] demonstrated the highest single-marker discrimination (AUC = 0.742, 95%CI: 0.667-0.817), and the four-biomarker model further improved discrimination (AUC = 0.839, 95%CI: 0.781-0.897; 10-fold cross-validated AUC = 0.804). A Youden-derived threshold of 0.518 yielded 78.9% sensitivity and specificity for distinguishing cases. A serum inflammation-endothelium-extracellular matrix biomarker panel showed good discriminative performance in distinguishing first-episode drug-naïve schizophrenia from controls in a case-control sample; external validation and potential recalibration in real-world cohorts are warranted. - Source: PubMed
Publication date: 2026/05/14
Yang QunSun XiaoyuJin SichangJiang FeiQiu JianchengBao JuanCao JingWang PeijuanLi ChuanweiZhang Xiaobin - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for hematological malignancies. However, it is often complicated by chronic graft-versus-host disease (cGVHD), a leading cause of late non-relapse morbidity and mortality. Early identification of patients at risk is therefore critical, yet reliable biomarkers are still lacking. In this study, we evaluated serum endothelial mediator profiles collected 1 year after allo-HSCT and their association with subsequent cGVHD development. Serum samples taken 1 year post-transplant from 82 transplanted patients, of whom 61% developed cGVHD, were analyzed for 19 mediators using Luminex and ELISA assays. Associations between mediator levels and cGVHD were assessed using statistical analysis, logistic regression, and hierarchical clustering. Six mediators, endocan, EMMPRIN, VCAM-1, MMP-1, MMP-8, and MMP-9; differed significantly between patients with and without cGVHD (P < 0.05). Endocan and VCAM-1 remained independently associated with cGVHD in multivariable regression adjusted for age, body mass index (BMI), and prior acute GVHD (aGVHD). Cluster analysis based on these mediators identified distinct patient subgroups. Clusters with generally lower mediator levels had fewer cases of cGVHD, whereas a central cluster with elevated levels showed a higher disease prevalence. Integration of clinical variables confirmed known risk factors, including older age, higher BMI, and previous aGVHD. The identified mediators are biologically linked to endothelial activation and extracellular matrix remodeling. This study is the first to demonstrate that a distinct endothelial- and matrix-remodeling-related serum mediator signature measured 1 year after allo-HSCT is associated with cGVHD. The identified patient clusters provide insight into disease biology and highlight potential biological markers of the disease. These findings support further prospective studies combining longitudinal mediator profiling with clinical data and advanced modeling to improve risk stratification and identify therapeutic targets for the prevention and treatment of cGVHD. - Source: PubMed
Publication date: 2026/02/28
Johansen SiljeSmits GuidoRye Kristin PaulsenHatfield Kimberley JoanneReikvam Håkon - Gestational diabetes mellitus (GDM) is a chronic metabolic disease occur during the pregnancy which is characterized via insulin resistance, hyperglycemia, inflammation and oxidative stress. Gigantol, a naturally occurring bibenzyl phytoconstituents showed the anti-inflammatory and antioxidant potential against various disease. The aim of the current study was to investigate the protective effect of gigantol against streptozotocin (STZ) induced GDM in female rats. Intraperitoneal administration of STZ (25 mg/kg) was used for induction the GDM in the rats and rats were received the oral administration of different doses of gigantol. The body weight, fetal weight, placental weight and placental index. The oral glucose tolerance test (OGTT), insulin tolerance test (ITT) estimated and calculate the area the under curve (AUC). Antioxidant parameters, inflammatory cytokines, inflammatory and apoptosis parameters were estimated. The mRNA expressions were also estimated. Gigantol treatment significantly improved the body weight, fetal weight and suppressed the placental weight and index. Gigantol remarkably altered the fasting blood glucose, plasma insulin, HOMA-IR and HOMA-β. Its also suppressed the blood glucose level during OGTT and ITT. Gigantol remarkably altered the level of AGE, visfatin, adiponectin, leptin, ICAM-1, VCAM-1, HO-1, Nrf2; antioxidant parameters, lipid parameters, inflammatory cytokines, inflammatory parameters and apoptosis parameters. Gigantol significantly altered the mRNA expression of Akt, MyD88, NF-κB, PI3K, TRL4, GSK-3β, Nrf2 and HO-1. Gigantol exhibited a protective effect against GDM via alterations in the Nrf2/HO-1, TLR4/MyD88/NF-κB, and PI3K/Akt/GSK-3β signaling pathways. - Source: PubMed
Su YeqingXing JiejieZheng Xian